Drug Trial Radar · NCT04958122
Cefixime Clinical Trial
Last checked: Nov 20, 2026Latest source record: May 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
400
Planned (sponsor's estimate)
Start
Jun 20, 2021
Primary completion
Jan 1, 2027
Study completion Jun 30, 2027
Sponsor
- Lead sponsor
- University of Southern CaliforniaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- AIDS Healthcare Foundation; Universidad Peruana Cayetano Heredia
- First posted
- Jul 12, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study aims to evaluate the efficacy of cefixime compared to benzathine penicillin G in the treatment of syphilis.
Conditions
- Syphilis
- Human Immunodeficiency Virus
Interventions
Cefixime 400mgDrug
Oral cefixime 400 mg, one capsule, twice a day for 10 days
benzathine penicillinDrug
Standard of care benzathine penicillin G, one intramuscular injection, 2.4MU
Primary outcomes
What the sponsor says the trial is designed to measure.
- Response to treatmentTime frame: 6 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of Southern California
Los Angeles, California · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.